Reassuring Market Adoption of Daybue Fuels Acadia’s Strategic Advancements, Analysts Boost Price Targets

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. 

For Q2, the company expects interim Daybue sales of $21-$23 million and Nuplazid sales of $140-$144 million. For Q3, Daybue (trofinetide) sales guidance stands at $45-$55 million.